|Videos|May 18, 2017

Lyme Disease: What Makes Diagnosis & Treatment Difficult?

Patricia Smith, President of the Lyme disease Association, discusses the difficulty of diagnosing and treating Lyme disease.

Patricia Smith, President of the Lyme disease Association, discusses the difficulty of diagnosing and treating Lyme disease.

Interview Transcript (slightly modified for readability)

“Patients are certainly facing a lot of problems getting diagnosed and getting treated. Those problems stem from the fact [that], first of all, even 43 years into Lyme disease, there’s still a lot of problems with recognizing Lyme disease. The testing is probably about 50% accurate (the test that’s being used now, the 2-step test).

Physicians aren’t always diagnosing Lyme, and so, patients can’t get diagnosed [easily or in a timely manner]. If it takes a long time for diagnosis, then it takes a longer time for a patient to get treatment. [In the] meantime, that bacteria [are] in their body replicating. Therefore, this is very problematic.”


Related to this article

Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.